Discontinuation of tyrosine kinase inhibitors in chronic myeloid leukemia: Recommendations for clinical practice from the French Chronic Myeloid Leukemia Study Group-Reference-Cited by-同舟云学术

Discontinuation of tyrosine kinase inhibitors in chronic myeloid leukemia: Recommendations for clinical practice from the French Chronic Myeloid Leukemia Study Group

Published:2018-05-03 Issue:14 Volume:124 Page:2956-2963
ISSN:0008-543X
Container-title:Cancer
language:en
Short-container-title:Cancer

Author:

Rea Delphine¹^ORCID,Ame Shanti¹,Berger Marc¹,Cayuela Jean-Michel¹,Charbonnier Aude¹,Coiteux Valérie¹,Cony-Makhoul Pascale¹,Dubruille Viviane¹,Dulucq Stéphanie¹,Etienne Gabriel¹,Legros Laurence¹,Nicolini Franck¹,Roche-Lestienne Catherine¹,Escoffre-Barbe Martine¹,Gardembas Martine¹,Guerci-Bresler Agnès¹,Johnson-Ansah Hyacinthe¹,Rigal-Huguet Françoise¹,Rousselot Philippe¹,Mahon François-Xavier¹,

Affiliation:

1. French Chronic Myeloid Leukemia Study Group, Bergonié Institute; Bordeaux France

Publisher

Wiley

Subject

Cancer Research,Oncology

Reference42 articles.

1. Tyrosine kinase inhibitors in chronic myeloid leukaemia: which, when, for whom?;Rosti;Nat Rev Clin Oncol.,2017

2. Life expectancy of patients with chronic myeloid leukemia approaches the life expectancy of the general population;Bower;J Clin Oncol.,2016

3. Impact of comorbidities on overall survival in patients with chronic myeloid leukemia: results of the randomized CML Study IV;Saussele;Blood.,2015

4. Frontline imatinib treatment of chronic myeloid leukemia: no impact of age on outcome, a survey by the GIMEMA CML Working Party;Gugliotta;Blood.,2011

5. European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013;Baccarani;Blood.,2013

Cited by 64 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Clinical efficacy and safety of first‐line nilotinib or imatinib therapy in patients with chronic myeloid leukemia—Nationwide real life data;Cancer Medicine;2024-09

2. European Stop Tyrosine Kinase Inhibitor Trial (EURO-SKI) in Chronic Myeloid Leukemia: Final Analysis and Novel Prognostic Factors for Treatment-Free Remission;Journal of Clinical Oncology;2024-06-01

3. Artificial Intelligence-Based Management of Adult Chronic Myeloid Leukemia: Where Are We and Where Are We Going?;Cancers;2024-02-20

4. How to improve treatment‐free remission eligibility in chronic myeloid leukaemia?;British Journal of Haematology;2023-12-26

5. The Success of Treatment Free Remission in Chronic Myeloid Leukaemia in Clinical Practice: A Single-Centre Retrospective Experience from South Africa;Advances in Hematology;2023-07-28